LiCl induces TNF-α and FasL production, thereby stimulating apoptosis in cancer cells

Cell Communication and Signaling

Volumn 9, Issue , 2011, Pages

  Kaufmann, Larissa ^a   Marinescu, Gabriela ^a   Nazarenko, Irina ^a,b   Thiele, Wilko ^a,b   Oberle, Carolin ^a   Sleeman, Jonathan ^a,b   Blattner, Christine ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALSTERPAULLONE; CASPASE 10; CASPASE 3; CASPASE 8; FAS LIGAND; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BID; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG TARGETING; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA INTERFERENCE;

RATTUS;

EID: 79956276679     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-9-15     Document Type: Article

References (51)

1. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. Beyaert R, Fiers W, FEBS Lett 1994 340 9 16 10.1016/0014-5793(94)80163-0 8119415 (Pubitemid 24094347)
2. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W, Eur J Cancer Clin Oncol 1986 22 419 426 10.1016/0277-5379(86)90107-0 3089802 (Pubitemid 16113799)
3. Rabbit tumor necrosis factor: mechanism of action. Ruff MR, Gifford GE, Infect Immun 1981 31 380 385 7216452 (Pubitemid 11136098)
4. Death receptor activation complexes: it takes two to activate TNF receptor 1. Sheikh MS, Huang Y, Cell Cycle 2003 2 550 552 14504472
5. The Fas signalling pathway and its role in the pathogenesis of cancer. Houston A, O'Connell J, Current Opinion in Pharmacology 2004 4 321 326 10.1016/j.coph.2004.03.008 15251123 (Pubitemid 38987056)
6. Signal transduction pathways. Molecular targets for lithium's actions. Manji HK, Potter WZ, Lenox RH, Arch Gen Psychiatry 1995 52 531 543 7598629
7. A molecular mechanism for the effect of lithium on development. Klein PS, Melton DA, Proc Natl Acad Sci USA 1996 93 8455 8459 10.1073/pnas.93.16.8455 8710892 (Pubitemid 26269579)
8. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Stambolic V, Ruel L, Woodgett JR, Curr Biol 1996 6 1664 1668 10.1016/S0960-9822(02)70790-2 8994831 (Pubitemid 27050234)
9. The role of protein phosphorylation in the hormonal control of enzyme activity. Cohen P, Eur J Biochem 1985 151 439 448 10.1111/j.1432-1033.1985. tb09121.x 2992967 (Pubitemid 16215774)
10. Judging a protein by more than its name: GSK-3. Woodgett JR, Sci STKE 2001 2001 E12 11579232
11. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Kulikov R, Boehme KA, Blattner C, Mol Cell Biol 2005 25 7170 7180 10.1128/MCB.25.16.7170-7180.2005 16055726 (Pubitemid 41105913)
12. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. He X, Saint-Jeannet JP, Woodgett JR, Varmus HE, Dawid IB, Nature 1995 374 617 622 10.1038/374617a0 7715701
13. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P, Biochem J 1994 303 Pt 1 21 26 7945242 (Pubitemid 24302893)
14. The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Saito Y, Vandenheede JR, Cohen P, Biochem J 1994 303 Pt 1 27 31 7945252 (Pubitemid 24302894)
15. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, et al. Eur J Biochem 2000 267 5983 5994 10.1046/j.1432-1327.2000.01673.x 10998059
16. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OM, J Biol Chem 1994 269 32187 32193 7798217
17. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Nikolakaki E, Coffer PJ, Hemelsoet R, Woodgett JR, Defize LH, Oncogene 1993 8 833 840 8384354 (Pubitemid 23087413)
18. Glycogen synthase kinase-3: functions in oncogenesis and development. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR, Biochim Biophys Acta 1992 1114 147 162 1333807 (Pubitemid 23008367)
19. Activation of protein kinase C increases phosphorylation of the L-myc trans-activator domain at a GSK-3 target site. Saksela K, Makela TP, Hughes K, Woodgett JR, Alitalo K, Oncogene 1992 7 347 353 1312697
20. p53 ubiquitination: Mdm2 and beyond. Brooks CL, Gu W, Mol Cell 2006 21 307 315 10.1016/j.molcel.2006.01.020 16455486 (Pubitemid 43163526)
21. Outcomes of p53 activation - spoilt for choice. Vousden KH, J Cell Sci 2006 119 5015 5020 10.1242/jcs.03293 17158908 (Pubitemid 46085181)
22. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. Turenne GA, Price BD, BMC Cell Biol 2001 2 12 10.1186/1471-2121-2-12 11483158 (Pubitemid 38597713)
23. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV, Science 1999 285 1733 1737 10.1126/science.285.5434. 1733 10481009 (Pubitemid 29428873)
24. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. Widlak P, Garrard WT, J Cell Biochem 2005 94 1078 1087 10.1002/jcb.20409 15723341 (Pubitemid 41420231)
25. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Soldani C, Scovassi AI, Apoptosis 2002 7 321 328 10.1023/A:1016119328968 12101391 (Pubitemid 34832256)
26. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, et al. Nat Chem Biol 2006 2 474 479 10.1038/nchembio809 16862141 (Pubitemid 44266309)
27. Apoptosis signaling pathways and lymphocyte homeostasis. Xu G, Shi Y, Cell Res 2007 17 759 771 10.1038/cr.2007.52 17576411 (Pubitemid 47411431)
28. Apoptosis control by death and decoy receptors. Ashkenazi A, Dixit VM, Curr Opin Cell Biol 1999 11 255 260 10.1016/S0955-0674(99)80034-9 10209153 (Pubitemid 29164042)
29. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, Wilting J, Sleeman JP, Cancer Res 2003 63 713 722 12566318 (Pubitemid 36158152)
30. Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. Knockaert M, Wieking K, Schmitt S, Leost M, Grant KM, Mottram JC, Kunick C, Meijer L, J Biol Chem 2002 277 25493 25501 10.1074/jbc.M202651200 11964410 (Pubitemid 34951864)
31. Neural and developmental actions of lithium: a unifying hypothesis. Berridge MJ, Downes CP, Hanley MR, Cell 1989 59 411 419 10.1016/0092-8674(89) 90026-3 2553271 (Pubitemid 19284456)
32. Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. York JD, Ponder JW, Majerus PW, Proc Natl Acad Sci USA 1995 92 5149 5153 10.1073/pnas.92.11.5149 7761465
33. The binding of lithium and of anionic metabolites to phosphoglucomutase. Ray WJ, Szymanki ES, Ng L, Biochim Biophys Acta 1978 522 434 442 623770 (Pubitemid 8274356)
34. GSK3 takes centre stage more than 20 years after its discovery. Frame S, Cohen P, Biochem J 2001 359 1 16 10.1042/0264-6021:3590001 11563964 (Pubitemid 32939202)
35. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H, J Surg Res 2010 159 640 644 10.1016/j.jss.2008.08.004 19394967
36. ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. Deming D, Geiger P, Chen H, Kunnimalaiyaan M, Holen K, J Surg Res 2010 161 28 32 10.1016/j.jss.2009.06.013 20031160
37. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, et al. Neoplasia 2010 12 357 365 20454507
38. Lithium inhibits carcinoid cell growth in vitro. Greenblatt DY, Ndiaye M, Chen H, Kunnimalaiyaan M, Am J Transl Res 2010 2 248 253 20589165
39. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, Li B, Prostate 2011 (ePub 2010 Oct. 28)
40. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Ghosh JC, Altieri DC, Clin Cancer Res 2005 11 4580 4588 10.1158/1078-0432.CCR-04-2624 15958644 (Pubitemid 40825649)
41. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q, Cancer Res 2005 65 9012 9020 10.1158/0008-5472.CAN-05-1226 16204075 (Pubitemid 41377393)
42. GSK-3: tricks of the trade for a multi-tasking kinase. Doble BW, Woodgett JR, J Cell Sci 2003 116 1175 1186 10.1242/jcs.00384 12615961 (Pubitemid 36410657)
43. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Kim K, Pang KM, Evans M, Hay ED, Mol Biol Cell 2000 11 3509 3523 11029052
44. In vitro effects of lithium chloride on TNF alpha and IL-6 production by monocytes from breast cancer patients. Arena A, Capozza AB, Orlando ME, Curro F, Losi E, Chillemi S, Mesiti M, Merendino RA, J Chemother 1997 9 219 226 9210006 (Pubitemid 27288413)
45. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. Kleinerman ES, Knowles RD, Blick MB, Zwelling LA, J Leukoc Biol 1989 46 484 492 2553837 (Pubitemid 19276889)
46. Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. Schotte P, Van Loo G, Carpentier I, Vandenabeele P, Beyaert R, J Biol Chem 2001 276 25939 25945 10.1074/jbc.M104014200 11342564 (Pubitemid 37412799)
47. Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Beyaert R, Vanhaesebroeck B, Suffys P, Van Roy F, Fiers W, Proc Natl Acad Sci USA 1989 86 9494 9498 10.1073/pnas.86.23.9494 2556714 (Pubitemid 20010453)
48. Application of the Cockcroft-Gault method to estimate lithium dosage requirement. Chiu CC, Shen WW, Chen KP, Lu ML, Psychiatry Clin Neurosci 2007 61 269 274 10.1111/j.1440-1819.2007.01654.x 17472595 (Pubitemid 46683992)
49. Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. Bender K, Gottlicher M, Whiteside S, Rahmsdorf HJ, Herrlich P, EMBO J 1998 17 5170 5181 10.1093/emboj/17.17.5170 9724653 (Pubitemid 28408483)
50. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Blattner C, Sparks A, Lane D, Mol Cell Biol 1999 19 3704 3713 10207094 (Pubitemid 29193830)
51. Hypophosphorylation of Mdm2 augments p53 stability. Blattner C, Hay T, Meek DW, Lane DP, Mol Cell Biol 2002 22 6170 6182 10.1128/MCB.22.17.6170-6182. 2002 12167711 (Pubitemid 34857837)